[Anticoagulation: assessment of benefits and risks].
Thromboembolism is a frequent complication of atrial fibrillation. As could be demonstrated by several placebo-controlled prospective studies in the recent years the rate of thromboembolism was reduced significantly by anticoagulation of nearly all kinds of atrial fibrillation. These results are challenging to weigh risks and benefits in every patient. The principles which have to consider in this calculation are discussed with regard to the knowledge derived from the controlled studies.
von Knorre
G H
GH
Abteilung für Kardiologie, Universität Rostock.
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D006329:Heart Conduction System / Q000503:physiopathology; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013617:Tachycardia, Supraventricular / Q000150:complications* / Q000503:physiopathology; D013923:Thromboembolism / Q000503:physiopathology / Q000517:prevention & control*
D000925:Anticoagulants
Antikoagulation: Abwägung von Nutzen und Risiko.